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Peritoneal and hemodialysis: I. Differences in patient charac- The variability in clinical outcomes between perito-
teristics at initiation. neal dialysis (PD) and hemodialysis (HD) was recently
Background. Comparisons of mortality outcomes between reviewed by Gokal and colleagues [1], who found thatperitoneal dialysis (PD) and hemodialysis (HD) patients have
there is a wide variation in mortality outcomes betweenshown varying results, which may be caused by the unequally
the therapies [1]. The contradictory results included (1)distributed clinical conditions of patients at initiation. To ad-
dress this issue, we evaluated the clinical characteristics of no differences in mortality between PD and HD [2–8],
105,954 patients at the initiation of PD and HD, using the U.S. (2) PD having a lower mortality than HD [9, 10], and (3)
national incidence data on treated end-stage renal disease from PD having a higher mortality than HD [11–13]. Nelson etthe Medical Evidence Form, 1995 to 1997.
al found that diabetic PD patients had lower mortalityMethods. A general linear model was used to analyze differ-
than diabetic HD patients [14], while Held et al pre-ences of age, albumin, creatinine, blood urea nitrogen (BUN),
and hematocrit; categorical data analysis to evaluate body mass sented the opposite findings [15]. Neither study found a
index (BMI), grouped into four categories: 19, 19–25 (25), difference in mortality between non-diabetic PD and
25–30 (30), and 30; and logistic regression to assess the like-
HD patients.lihood of initiating PD versus HD. Diabetics (DM) were ana-
These inconsistent results raise concerns about thelyzed separately from non-diabetics (NDM). Explanatory vari-
ables in the logistic regression included incidence year, race, reliability of the mortality comparison itself. It has been
gender, age, BMI, albumin, creatinine, BUN, and hematocrit. suggested that, because of complex factors such as pa-
Race included white and black. Age was categorized into four tient choice, comorbidity, failure of vascular access, and
groups: 20–44, 45–64, 65–74, and 75.
payment systems, the patients’ clinical conditions at initi-Results. At the initiation of dialysis PD patients were ap-
ation are not equally distributed between PD and HD.proximately 6 years younger (P  0.0001) than HD patients.
PD patients also had higher (P 0.0001) albumin (0.35 g/dL Completion of the Medical Evidence Form 2728, up-
for DM and 0.23 g/dL for NDM) and hematocrit (1.64% dated in April 1995, is now required at the first service
for DM and 1.71% for NDM) levels, and lower (P  0.04) of end-stage renal disease (ESRD). The updated formBUN (8.75 mg/dL for DM and -5.24 mg/dL for NDM) and
includes data on patient comorbidity and biochemistry,creatinine (0.51 mg/dL for DM and 0.23 mg/dL for NDM)
providing an opportunity to compare clinical conditionslevels than HD patients. Whites had a higher (P  0.0001)
likelihood of starting PD than blacks, and patients with BMI of PD and HD patients upon initiation of treatment.
19 had a lower (P  0.0001) chance of beginning on PD. Our study used the data from the Medical Evidence
Conclusion. PD patients had favorable clinical conditions Form to evaluate the clinical characteristics, includingat the initiation of dialysis, which should be taken into consid-
body mass index and laboratory test values, of patientseration when comparing dialysis outcomes between the two
at the initiation of PD and HD between 1995 and 1997.modalities.
METHODS
Patient characteristics
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Data from the Medical Evidence Form (HCFA 2728)stage renal disease, Medical Evidence Form, Health Care Financing
Administration. for treated ESRD patients was obtained from the Health
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tion on laboratory tests, height, and weight for the yearsand in revised form September 25, 2001
Accepted for publication September 27, 2001 1995 to 1997.
Each patient’s initial dialysis modality, either PD or 2002 by the International Society of Nephrology
734
Xue et al: Initial clinical conditions of PD and HD patients 735
Table 1. Percentage of patients on peritoneal dialysis (PD) and hemodialysis (HD) by race and gender
Diabetics Non-diabetics
Race Gender N patients PD % HD % N patients PD % HD %
White Male 16,014 15.39 84.61 22,737 11.91 88.09
Female 14,925 13.30 86.70 15,560 14.19 85.81
Black Male 6,164 8.37 91.63 11,625 6.68 93.32
Female 9,160 7.61 92.39 9,769 8.78 91.22
HD, was determined from the Medical Evidence Form. model (GLM) [17] with dialysis therapies, race, and gen-
The clinical data elements included race, gender, age, dia- der as independent variables.
betic status, height, weight, serum albumin, creatinine, Logistic regression analysis was used to evaluate the
blood urea nitrogen (BUN), and hematocrit at the initia- likelihood of initiating on PD or HD [22]. The explana-
tion of dialysis. Body mass index (BMI) was calculated tory variables were incidence year (1996 and 1997; 1995
using the formula: body weight (kg) height (m2). Creat- was reference), race (white; black was reference), gender
inine clearance, hemoglobin, and urea clearance were (male; female was reference), age (20–44, 45–64, and
not included in the data analysis because the creatinine 65–74; age 75 was reference), BMI (19, 25–30 and
clearance value recorded on the form was simply calcu- 30; BMI 19–25 was reference), albumin, BUN, creati-
lated from serum creatinine [16], because hemoglobin nine, and hematocrit. The biochemical data were treated
has the same indication as hematocrit, and because only as continuous variables in the model. Odds ratios (OR)
2.2% of patients had urea clearance data. Native Ameri- and their 95% confident limits (CL) were determined
cans, Asians, and patients younger than 20 also were from the logistic procedure.
excluded due to the small number of patients.
After the exclusions 158,419 incidence patients in the
RESULTSdata set had complete information for race, gender, age,
Racial and gender differences between PD and HDand diabetic status. Of these patients 89.1% had BMI
are reported in Table 1. A higher (P  0.0001) percent-data, 72.6% had albumin data, 82.7% had BUN data,
age of whites started on PD than of blacks in both gen-88.4% had creatinine data, and 83.8% had hematocrit
ders and for both diabetics and non-diabetics. Among dia-data. Because patients with missing information on any
betics there were higher (P 0.0001) percentages of whitevariables would be omitted in the process of statistical
and black females starting on PD than of their male coun-analysis (for example, logistic regression), we analyzed
terparts. In diabetics, however, a lower (P 0.0001) per-only those who had complete data for BMI, albumin,
centage of white females initiated on PD compared withcreatinine, and BUN as well as data for race, gender,
their male counterparts. No difference (P 0.08) was ob-age, and diabetic status. The final data set contained
served between black diabetic males and females.105,954 patients, 66.9% of the total 158,419. The final
After adjusting for other factors in the logistic regres-data set was compared to the initial one using the 2
sion model, the odds ratio (and its 95% CL) of whitestest, and no difference was found (P  0.1) in the per-
versus blacks (blacks were reference, OR 1.0) startingcentage of patients on PD and HD.
on PD was 1.863 (range 1.735–2.000, P  0.0001) in
Statistical analysis diabetics (Fig. 1), indicating that diabetic whites had an
86.3% higher likelihood than diabetic blacks to initiateAll data were analyzed using SAS (SAS, Inc., Cary,
on PD. In non-diabetics, the odds ratio was 1.969 (1.847–NC, USA) [17]. Because diabetics are clinically different
2.098, P  0.0001), that is, non-diabetic whites had afrom non-diabetics [18–20], the two groups of patients
96.9% higher likelihood than non-diabetic blacks to initi-were separated in our analysis. The proportion of pa-
ate on PD (Fig. 1). No difference (1.042, 0.981–1.107,tients on PD and HD at initiation was analyzed using
P  0.18) between genders was observed in diabeticsthe Mantel-Haenszel method, with race and gender as
(Fig. 2), while non-diabetic males (0.784, 0.741–0.828,strata. Body mass index was grouped into 19, 19–25
P  0.0001) had a lower chance of starting on PD than(25), 25–30, (30), and 30, representing underweight,
females (females were reference, OR  1.0).appropriate weight, overweight, and obesity, respectively.
Body mass index by dialysis therapy is shown in Ta-We compared the proportion of patients between PD
ble 2. There was a clear pattern in which patients initiat-and HD within each BMI group using categorical data
ing on PD were less likely (P 0.0001) to be underweightmodeling [21]. Patient age, hematocrit, and serum con-
(BMI 19) than those on HD across all race, gender,centrations of albumin, creatinine, and BUN at the initia-
tion of ESRD were analyzed using the general linear and diabetic groups, except for white diabetic females.
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Fig. 2. Odds ratio of males versus females for PD (female was refer-Fig. 1. Odds ratios of whites versus blacks for peritoneal dialysis (PD;
ence; OR  1.0). In non-diabetics, males had a lower likelihood ofblack was reference; OR 1). Whites had a higher likelihood of initiat-
initiating on PD than females. Lines at the top of bars indicate theing therapy on PD than blacks in both diabetics and non-diabetics.
range of 95% confidence limits of the odds ratios.Lines at the top of bars indicate the range of 95% confidence limits of
the odds ratios.
Table 2. Percentage of body mass index by modality, race, and gender
Body mass index
Race Gender Modality N patients 19 19–25 25–30 30
Diabetics White Male PD 2,465 3.20 42.23 37.12 17.44
HD 13,549 4.86 43.70 32.61 18.82
Female PD 1,985 4.94 39.04 29.32 26.70
HD 12,940 4.93 34.16 28.13 32.78
Black Male PD 516 1.74 34.11 38.37 25.78
HD 5,648 5.67 37.92 32.22 24.19
Female PD 697 2.30 31.42 29.56 36.73
HD 8,463 5.40 29.42 28.61 36.57
Non-diabetics White Male PD 2,709 4.02 45.74 36.14 14.10
HD 20,028 9.25 51.44 27.60 11.71
Female PD 2,208 9.38 45.92 27.31 17.39
HD 13,352 14.89 45.88 22.34 16.89
Black Male PD 776 5.93 44.20 32.60 17.27
HD 10,849 10.79 47.70 26.59 14.91
Female PD 858 8.51 38.58 23.66 29.25
HD 8,911 12.91 41.13 23.15 22.81
However, white female PD patients with diabetes had a proximately six years younger (P  0.0001) than that of
HD patients across all race, gender, and diabetic groupshigher (P  0.0001) proportion of appropriate weight
(BMI 19–25) than HD patients. After adjusting for other (Table 3 and Fig. 4). Compared with diabetic patients
aged 75 (age 75 was reference, OR  1.0), diabeticsfactors in the logistic regression model, the odds ratios
indicated that patients with BMI19 had a 34.3% (0.657, aged 20–44, 45–64, and 65–74 were 457% (5.570, 4.891–
6.344, P 0.0001), 229% (3.288, 2.924–3.697, P 0.0001),0.561–0.769, P  0.0001) and 36.8% (0.632, 0.567–0.704,
P  0.0001) lower chance of starting on PD compared and 66% (1.659, 1.465–1.880, P  0.0001), respectively,
more likely to start on PD. The same pattern was ob-with those having BMI 19–25 (BMI 19–25 was reference,
OR  1.0) in diabetics and non-diabetics, respectively served in non-diabetics, in whom odds ratios were 3.851
(3.505–4.231, P  0.0001) for patients aged 20–44, 3.017(Fig. 3). In diabetics, patients with BMI 30 had a lower
(0.808, 0.748–0.872, P  0.0001) chance and those with (2.773–3.283, P 0.0001) for those aged 45–64, and 1.501
(1.368–1.647, P  0.0001) for those aged 65–74.BMI 25-30 had a higher (1.079, 1.007–1.156, P  0.03)
chance of starting on PD compared with BMI 19–25. In Patients initiating on PD had higher (P  0.0001)
serum concentrations of albumin and hematocrit andnon-diabetics, patients with BMI 25–30 had a higher
(1.172, 1.101–1.248, P 0.0001) chance of starting on PD lower levels of BUN (P  0.0001) and creatinine (P 
0.04) than those on HD across all races, genders, andthan those with BMI 19–25. No difference was observed
between BMI 30 (0.945, 0.876–1.020, P  0.15) and diabetic groups (Table 3). In general, diabetic PD pa-
tients had 0.35 g/dL (10.7%) higher albumins, 1.64%BMI 19–25.
The average age of patients initiating on PD was ap- (5.9%) higher hematocrits, 8.75 mg/dL (9.1%) lower
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Fig. 3. Odds ratio of body mass index for PD (body mass index, BMI, Fig. 4. Odds ratio of age for PD (age group 75 was reference; OR 
1.0). Patients aged 20–44, 45–64, and 65–74 had higher likelihoods of19–25 was reference; OR  1.0). Among diabetics, patients with BMI
19 and 30 had lower and those with BMI 25–30 had higher likeli- initiating on PD than those aged 75. Lines at the top of bars indicate
the range of 95% confidence limits of the odds ratios.hoods of initiating on PD than those with BMI 19–25. In non-diabetics,
patients with BMI 19 had a lower and those with BMI 25–30 a higher
likelihood of initiating on PD compared with those with BMI 19–25.
Lines at the top of bars indicate the range of 95% confidence limits of
the odds ratios.
Table 3. Average age and serum biochemicals and their standard deviations at initiation of dialysis
Age Albumin Creatinine BUN Hematocrit
years g/dL mg/dL mg/dL %
Race Gender Modality N patient Mean SD Mean SD Mean SD Mean SD Mean SD
Diabetics White F PD 1,985 55.6 13.6 3.30 0.58 6.50 2.27 83.4 27.4 29.8 5.5
HD 12,940 62.5 12.6 3.06 0.60 6.52 2.36 89.2 30.9 28.3 5.2
M PD 2,465 55.3 13.3 3.39 0.58 7.51 2.46 89.5 27.3 30.0 5.5
HD 13,549 60.7 13.3 3.17 0.61 7.69 2.77 96.2 31.8 28.4 5.3
Black F PD 697 56.4 12.3 3.23 0.60 7.67 2.79 79.1 25.5 28.4 5.4
HD 8,463 61.6 12.2 3.07 0.61 7.84 2.87 83.3 28.9 27.1 5.2
M PD 516 55.2 11.5 3.36 0.58 9.08 3.05 85.2 25.0 29.0 5.6
HD 5,648 58.9 12.2 3.12 0.63 9.16 3.62 93.5 32.0 27.4 5.5
Non-diabetics White F PD 2,208 56.2 15.9 3.66 0.61 7.75 2.97 83.9 28.4 29.7 5.5
HD 13,352 64.9 16.0 3.27 0.60 7.84 3.41 92.2 34.2 28.0 5.5
M PD 2,709 58.8 15.9 3.69 0.62 9.01 3.42 93.0 29.8 29.8 5.8
HD 20,028 64.5 16.0 3.35 0.65 9.07 3.80 100.0 35.0 28.5 5.7
Black F PD 858 48.6 14.8 3.46 0.69 8.74 3.93 80.8 27.4 27.6 5.7
HD 8,911 56.9 17.3 3.20 0.71 9.81 4.38 89.7 33.1 26.3 5.7
M PD 776 46.9 14.8 3.44 0.80 11.73 4.91 89.6 30.5 28.6 5.9
HD 10,849 52.9 16.1 3.19 0.75 12.13 5.45 101.7 36.2 26.9 5.9
BUNs and 0.51 mg/dL (5.7%) lower creatinines com- (0.994, 0.993–0.995, P  0.0001) and 0.7% (0.993, 0.992–
pared with diabetic HD patients. Non-diabetic PD pa- 0.994, P  0.0001) decrease, and each 1 mg/dL increase
tients had 0.23 g/dL (7.4%) higher albumins, 1.71% in creatinine was associated with a 1.4% (0.986, 0.974–
(6.1%) higher hematocrits, 5.24 mg/dL (5.8%) lower 0.998, P  0.02) and 2.2% (0.978, 0.970–0.987, P 
BUN values, and 0.23 mg/dL (3.0%) lower creatinine 0.0001) decrease in the odds of the initiation on PD in
values compared with non-diabetic HD patients. diabetics and non-diabetics, respectively.
Odds ratios from the logistic regression indicated that
each 1 g/dL increase in serum albumin was associated
with a 100.7% (2.007, 1.910–2.110, P 0.0001) and 104.4% DISCUSSION
(2.044, 1.958–2.134, P  0.0001) increase in the odds of
This study clearly demonstrates the unequally distrib-the initiation on PD in diabetics and non-diabetics, re-
uted clinical conditions of patients at initiation betweenspectively (Fig. 5). Each 1% increase in hematocrit was
the two dialysis therapies. Compared with HD patients,associated with a 4.8% (1.048, 1.042–1.054, P  0.0001)
both diabetic and non-diabetic PD patients had a higherand 3.0% (1.030, 1.025–1.035, P 0.0001) increase, each
1 mg/dL increase in BUN was associated with a 0.6% likelihood of being white and younger, a lower likelihood
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appropriate weight or who are overweight [34]. Under-
weight was observed as a risk factor for first-year mortal-
ity of dialysis patients, but overweight (BMI 27.5) was
not [34]. Since both diabetic and non-diabetic PD pa-
tients in this study were less likely to be underweight,
they would be expected to have a lower risk of mortality
than HD patients.
Serum creatinine levels at the initiation of dialysis may
reflect the stage of referral to a nephrologist for uremia
treatment. A number of studies have reported that pa-
tients with late referral to nephrologists had higher serum
concentrations of creatinine and BUN compared with
those referred early [35, 36]. Serum creatinine or esti-
mated creatinine clearance may not be a reliable markerFig. 5. Odds ratio of albumin, creatinine, blood urea nitrogen (BUN),
of residual renal function at the initiation of dialysis. Aand hematocrit levels (as continuous variables) for PD. An increase in
albumin and hematocrit was associated with an increase in the likelihood trend of lower serum creatinine levels at the initiation
of initiation on PD, while an increase in BUN and creatinine was of dialysis has been reported in the United States be-associated with a decrease in the likelihood of initiation on PD. Lines
tween 1963 and 1996, from 14.5 mg/dL during 1963–1977at the top of bars indicate the range of 95% confidence limits of the
odds ratios. to 8.5 mg/dL during 1995–1996 [37], suggesting that pa-
tients with renal disease have started dialysis earlier in
recent years. We also observed decreased serum creati-
nine levels in the study period. The relationship betweenof being underweight, and had higher serum albumin and
creatinine and BUN levels and the severity of renal dis-hematocrit values, and lower BUN and creatinine levels.
ease could not be determined in this retrospective studySerum albumin concentrations reflect nutritional sta-
because many factors such as nutrition, metabolism rate
tus as well as clinical disease, chronic inflammatory con-
of muscle mass, and secretion of creatinine by renal
ditions, and disease severity at the initiation of dialysis. tubules could affect concentrations of serum creatinine
A change in serum albumin concentrations is a slow pro- and BUN [38, 39]. High serum creatinine and BUN lev-
cess [23]. When protein and caloric malnutrition exists, els, for instance, can be related to a high protein or
catabolism of body protein accelerates. Muscle break- creatine diet or to high lean body mass.
down occurs to maintain the amino acid supply for the Biochemical and body mass index data have not been
synthesis of visceral protein such as albumin. When mal- included in many previous studies comparing mortality
nutrition continues, the concentrations of serum pro- outcomes between PD and HD. Most studies include
teins, including albumin, fall [24]. Previous studies have race, age, gender, and diabetic status, and report that
demonstrated that the serum concentration of albumin whites and younger patients are more likely to initiate
is one of the strongest predictors of mortality outcomes on PD than patients who are blacks or older. Many
in both PD and HD patients, and that a high serum studies, in addition, have demonstrated that blacks have
albumin is associated with a low risk of mortality [20, a lower mortality than whites and young patients have
25–28]. In addition, more recent data have shown that lower mortality than older ones in both PD and HD
a low serum albumin value may reflect a response to therapies [19, 40–42]. The number of blacks and younger
chronic inflammation [29]. PD patients with the higher patients starting on PD may, therefore, affect the com-
initial serum concentration of albumin demonstrated in parison of mortality outcomes between the modalities.
this study therefore would be expected to have a lower Our consistent finding that non-diabetics had higher
risk of mortality compared with HD patients. levels of albumin, creatinine, and BUN at initiation than
Weight loss, particularly loss of muscle mass, is a con- diabetics has been reported previously [19, 20], and sug-
sequence of long-term protein malnutrition. It is well gests that diabetic and non-diabetic ESRD patients are
known that obesity is associated with a high death rate clinically different at initiation.
in the general population because excess body fat is asso- This study did not include co-morbid conditions re-
ciated with cardiovascular disease, cancers, and other corded on the Medical Evidence Form because we found
medical conditions [30]. However, excess body weight in that they did not closely match those recorded in the
certain age groups may not necessarily be associated with HCFA Medicare claims [abstract; Xue, Perit Dial Int 21
high mortality [31, 32]. Underweight also is associated (Suppl 1):S84, 2001]. The same findings were reported
with high mortality in the general population [33]. Un- from the CHOICE Study using medical records [43].
derweight dialysis patients are more likely to fall ill and In summary, we observed clear unequally distributed
clinical conditions of patients at initiation with regard torecover more slowly from illness than patients who have
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14. Nelson CB, Port FK, Wolfe RA, et al: Comparison of continuousdialysis therapies. Patients on PD had more favorable
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